Intelligent Bio Solutions Inc.INBS

Intelligent Bio Solutions Inc. likes to describe itself as a medical-technology outfit bringing “intelligent, rapid, non-invasive testing solutions” to workplace and safety-critical markets. The latest press burst claims it has ticked every cybersecurity and software box ahead of its FDA 510(k) submission, positioning the company for a multi-billion-dollar U.S. drug-screening market. The SEC filing, however, tells the quieter story: revenue of $1.1 million in the three months to 31 March 2026, alongside a net loss of $2.9 million and operating cash burn of $8.7 million. The gap between the PowerPoint and the cash-flow statement is large enough to park a small lorry.

The company’s flagship product is the Intelligent Fingerprinting Drug Screening System, which analyses fingerprint sweat to detect drug use. The official site explains how the technology supports workplace safety across safety-critical industries, government and law-enforcement settings. The site also shows a product image and a newsroom page, but it stops short of publishing any signed contracts, signed purchase orders, or audited sales volumes. The gap between the polished product story and the filed numbers sits at roughly $8.7 million, give or take a doughnut.

For the quarter ended 31 March 2026, Intelligent Bio Solutions reported revenue of $1.1 million, up from $902,138 a year earlier but still covering less than one-fifth of the quarter’s $2.9 million net loss. Operating income was a matching loss of $2.9 million, cash and equivalents stood at $6.9 million, and net cash used in operating activities was $8.7 million. Inventory fell slightly by $37,746 to $597,469, while capex was a modest $125,731. Diluted earnings per share were negative $1.80 on 1.6 million diluted shares. The filing stops there; it does not break down the revenue mix, customer concentration, or gross margins behind the numbers.

The company has issued a flurry of 8-Ks and press releases in recent weeks to flag progress on software and cybersecurity milestones for its 510(k) submission. On 23 July 2026 it announced it had addressed all cybersecurity and software-related review items; on 21 July 2026 it said precision testing had confirmed consistent, reliable results across varied manufacturing conditions; on 16 June 2026 it filed a notice of initiation of a multi-site method comparison study; and on 2 May 2026 it announced the study itself. These are process updates, not revenue recognition events, and the filings do not quantify any commercial impact. The company’s latest 13G filing shows a passive institutional holder but offers no insight into trading liquidity or market depth.

There is no TradingView route supplied in the evidence, so we cannot quote a price or volume trend. The only market mechanism we can describe is the filing pipeline: quarterly reports, 8-Ks, and a 13G window into passive ownership. The next material evidence will be the company’s 10-K for the year ended 31 March 2026, any updated 10-Q, or an FDA decision letter once submitted. Until then, the story is the filing story.